MARKET

APVO

APVO

Aptevo Therapeutics Inc
NASDAQ
4.770
-0.025
-0.52%
After Hours: 4.770 0 0.00% 16:10 05/15 EDT
OPEN
4.670
PREV CLOSE
4.795
HIGH
4.805
LOW
4.670
VOLUME
11.67K
TURNOVER
--
52 WEEK HIGH
258.01
52 WEEK LOW
3.800
MARKET CAP
5.64M
P/E (TTM)
-0.0547
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Aptevo Therapeutics (APVO)
TipRanks · 2d ago
Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M
TipRanks · 3d ago
Aptevo Therapeutics reports Q1 results
Seeking Alpha · 3d ago
Aptevo says RAINIER trial on track for 2026 completion, Phase 2 dose selection
PUBT · 3d ago
Weekly Report: what happened at APVO last week (0504-0508)?
Weekly Report · 5d ago
Aptevo reports 87% clinical benefit in frontline AML patients in RAINIER trial
TipRanks · 05/07 06:10
Aptevo Highlights Strong Phase 1b AML Trial Results
TipRanks · 05/06 20:52
Aptevo Therapeutic Announces 87% clinical benefit rate And 81% Remission Rate In Its RAINIER Frontline Acute Myeloid Leukemia Trial, RAINIER Remains On Schedule For 2026 Completion And Phase 2 Dose Selection
Benzinga · 05/06 12:10
More
About APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.

Webull offers Aptevo Therapeutics Inc stock information, including NASDAQ: APVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APVO stock methods without spending real money on the virtual paper trading platform.